Compare · ALPA vs BSX
ALPA vs BSX
Side-by-side comparison of Alpha Healthcare Acquisition Corp. III (ALPA) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALPA and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 379.4x ALPA ($190.2M).
- BSX has hit the wire 12 times in the past 4 weeks while ALPA has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for ALPA).
- Company
- Alpha Healthcare Acquisition Corp. III
- Boston Scientific Corporation
- Price
- $9.82-0.41%
- $48.56-0.60%
- Market cap
- $190.2M
- $72.16B
- 1M return
- -
- -13.30%
- 1Y return
- -
- -51.46%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 25
Alpha Healthcare Acquisition Corp. III
Alpha Healthcare Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest ALPA
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits